ArticleCNS neuroscience & therapeutics2026
The Mechanism Underlying the Abnormal Expression of α-Synuclein in the Cortical Lesions of Patients With FCD Type IIb and TSC.
Article in CNS neuroscience & therapeutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
aimsThis study aims to investigate the underlying mechanisms of abnormal expression of α-synuclein (α-syn) in cortical lesions of focal cortical dysplasia IIb (FCD IIb) and tuberous sclerosis complex (TSC).
methodsCortical lesions of patients with FCD IIb and TSC were obtained during the surgery, FCD rats were generated by in utero X-ray radiation. Immunostaining, RT-PCR, Western blotting, and electroencephalography recording were conducted in this study. α-syn was intraventricularly injected; mTOR inhibitor (rapamycin) and glutamate transporter-1 (GLT-1) enhancer (ceftriaxone sodium) were intraperitoneally injected before the following experiments.
resultsmTOR and p-mTOR expressed in the dysmorphic neurons, vimentin-positive balloon cells, and giant cells, whereas the mTOR/p-mTOR ratio was decreased in FCD IIb and TSC lesions. α-syn was decreased, while p-α-syn was increased in the cortex of FCD animals, whereas they were rescued by inhibition of mTOR with rapamycin. The expression of GLT-1 was decreased and modulated by rapamycin in FCD animals. Enhancement of the function of GLT-1 with ceftriaxone ameliorated α-synucleinopathy and seizure activities in FCD animals. Additionally, intracerebroventricular injection of α-syn exerted anti-seizure effects.
conclusionsOur results showed that modulation of the mTOR/GLT-1 pathway ameliorated α-synucleinopathy and seizure activities in FCD, providing insights for understanding the epileptogenic mechanisms of FCD IIb and TSC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.